Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

CMChristine M. McMahonDNDeedra NicoletAMAlice S. Mims

Discussion

Loading...

Member takes

Overview

Analysis shows poor survival in older patients with 11q23/KMT2A-r AML, indicating a need for better therapies.

Key Points

  • To analyze the clinical characteristics and treatment outcomes of adult patients with 11q23/KMT2A-rearranged Acute Myeloid Leukemia.
  • Analyzed data from the US MARROW consortium and Flatiron database involving 325 patients.
  • Assessed treatment patterns including intensive chemotherapy and HMA-based regimens.
  • Performed statistical comparisons of survival outcomes among diverse patient groups.
  • 3-year overall survival was 28% and 3-year disease-free survival was 33% in all patients.
  • Older patients (≥60 years) exhibited significantly poorer survival outcomes compared to younger patients.
  • Patients treated with intensive chemotherapy had higher rates of complete remission compared to those receiving HMA therapies.

Cite This Study

McMahon et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6fahttps://doi.org/10.1182/blood-2025-292
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium2025
  2. 2Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study2024 · 34 citations
  3. 3A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  4. 4Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia2025
  5. 5Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025